notice. KGOG 2025 캠페인 희망 더하기, 부인암 연구기금 마련 걷기대회. more

Bureau of the Korean Gynecologic Oncology Group 2-ho, 2nd Floor, 32, Nambusunhwan-ro 333-gil, Seocho-gu, Seoul 06725, Korea

Dec 6, 2021 · Methods. The KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited from seven KGOG sites.

2.3. Interaction with Other International Research Organizations. Since its establishment, the KGOG has collaborated with prominent international institutions leading multi-center research, such as the GOG Legacy and NRG in the United States, European Network for Gynaecological Oncological Trial group (ENGOT) in Europe, and the Gynecologic Cancer InterGroup (GCIG).

INTRODUCTION. On November 19, 2021, 4 clinical trial groups, the Japanese Gynecologic Oncology Group (JGOG), the Korean Gynecologic Oncology Group (KGOG), the Taiwanese Gynecologic Oncology Group (TGOG), and the Chinese Gynecologic Cancer Society (CGCS) collaborated to establish the East Asian Gynecologic Oncology Trial Group (EAGOT).

ClinicalTrials.gov Identifier: NCT04734665. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Background: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 antibody) to chemotherapy in treating this cancer can increase progression ...

Chairman: Professor Ki-dong Kim 06.01. The 1 st JGOG-KGOG Web Meeting-Cervical Cancer Committee (Webmeeting) . 07.13. The 2 nd JGOG-KGOG Web Meeting-Ovary Cancer Committee (Webmeeting) . 08.06. The 3 rd JGOG-KGOG Web Meeting-Uterine Cancer Committee (Webmeeting) . 08.15. KGOG protocol committee 200th Anniversary "2020 the 30th KGOG Symposium and Workshop" (Sheraton Seoul Palace Gangnam)

In the original cohort (O) of KGOG 3046 study (NCT03899610) on newly diagnosed advanced-stage epithelial ovarian cancer (aEOC), patients receiving neoadjuvant chemotherapy (NAC) with durvalumab [D] and multiple low dose of tremelimumab [T] exhibited promising long-term survival outcomes. After completing enrollment of the original cohort, an expansion cohort (E) was initiated with a regimen of ...

Apr 14, 2022 · Initial data from the phase 2 KGOG 3046 trial (NCT03899610) that were presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting demonstrated early promise of dual immune checkpoint inhibitors durvalumab (Imfinzi) and tremelimumab in combination with chemotherapy as neoadjuvant therapy for …